TUM Library catalog › Details for: Statistical Approaches in Oncology Clinical Development : Current Paradigm and Methodological Advancement /

Normal view MARC view ISBD view

Statistical Approaches in Oncology Clinical Development : Current Paradigm and Methodological Advancement / edited by Satrajit Roychoudhury and Soumi Lahiri.

Contributor(s): Roychoudhury, Satrajit [editor.] | Lahiri, Soumi [editor.] | Taylor and FrancisMaterial type: Text

TextSeries: Chapman & Hall/CRC Biostatistics Series: Publisher: Boca Raton, FL : Chapman and Hall/CRC, 2018Edition: First editionDescription: 1 online resource (236 pages) : 79 illustrations, text file, PDFContent type: text Media type: computer Carrier type: online resourceISBN: 9781315154435(e-book : PDF)Subject(s): MEDICAL / Biostatistics | MEDICAL / Pharmacology | Antineoplastic agents -- Development | Cancer -- Chemotherapy | Drugs -- TestingGenre/Form: Electronic books.Additional physical formats: Print version: : No titleDDC classification: 616.99/4061 LOC classification: RC271 | .C5Online resources: Click here to view Also available in print format.

Contents:

1. Introduction -- [Ohad Amit] -- 2. Statistical Considerations in Phase I Oncology Trials -- [Simon Wandel and Satrajit Roychoudhury] -- 3. ExposureResponse Analysis in Oncology Trials -- [Yi-Lin Chiu and Balakrishna S. Hosmane] -- 4. Statistical Measures of Interaction for Evaluating a Predictive -- Biomarker -- [Jaya Satgopan] -- 5. Design Considerations for Phase II Oncology Clinical Trials -- [Jared C. Foster, Jennifer Le-Rademacher, and Sumithra J. Mandrekar] -- 6. Precision Medicine and Associated Challenges -- [Rajesh Talluri and Sanjay S. Shete] -- 7. Use of Adaptive Design in Late-Stage Oncology Trials -- [Satrajit Roychoudhury, Arunava Chakravartty, and Pabak Mukhopadhyay] -- 8. Safety Monitoring and Analysis in Oncology Trials -- [Anastasia Ivanova, Qi Jiang, Olga Marchenko, and Richard C. Zink] -- 9. Quality of Life -- [Diane Fairclough] -- 10. Impact of Evolving Regulatory Pathways on Statistical -- Considerations in Oncology Clinical Trials -- [Rajeshwari Sridhara].

Abstract: Statistical Approaches in Oncology Clinical Development : Current Paradigm and Methodological Advancement presents an overview of statistical considerations in oncology clinical trials, both early and late phase of development. It illustrates how novel statistical methods can enrich the design and analysis of modern oncology trials. The authors include many relevant real life examples from the pharmaceutical industry and academia based on their first-hand experience. Along with relevant references, the book highlights current regulatory views. The book covers all aspects of cancer clinical trial starting from early phase development. The early part of the book covers novel phase I dose escalation design, exposure response analysis, and innovative phase II design. This includes early development strategy for cancer immunotherapy trials. The contributors also emphasized the role of biomarker and modern era of precision medicine. The second part focuses on the late stage development. This includes the application of adaptive design, safety analysis, and quality of life (QoL) data analysis. The final part discusses current regulatory perspective and challenges. Features: Covers a wide spectrum of topics related to real-life statistical challenges in oncology clinical trials. Provides a comprehensive overview of novel statistical methods to improve trial design and statistical analysis. Detailed case studies illustrate the real life applications. Satrajit Roychoudhury is a Senior Director and a member of the Statistical Research and Innovation group in Pfizer Inc. Prior to joining; he was a member of Statistical Methodology and consulting group in Novartis. He has 11 years of extensive experience in working with different phases of clinical trial. His area of research includes early phase oncology trials, survival analysis, model informed drug development, and use of Bayesian methods in clinical trials. He is industry co-chair for the ASA Biopharmaceutical Section Regulatory-Industry Workshop and has provided statistical training in major conferences including the Joint Statistical Meetings, ASA Biopharmaceutical Section Regulatory-Industry Workshop, and ICSA Applied Statistics Symposium. Soumi Lahiri has 12 years of extensive experience in working different therapeutic areas. She is the former Director of Biostatistics in Clinical Oncology, GlaxoSmithKline. She has also worked in the oncology division of Novartis Pharmaceutical Company for two years. She is an active member of the ASA Biopharmaceutical section and former chair of the membership committee.

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes

No physical items for this record

Includes bibliographical references and index.

Statistical Approaches in Oncology Clinical Development : Current Paradigm and Methodological Advancement presents an overview of statistical considerations in oncology clinical trials, both early and late phase of development. It illustrates how novel statistical methods can enrich the design and analysis of modern oncology trials. The authors include many relevant real life examples from the pharmaceutical industry and academia based on their first-hand experience. Along with relevant references, the book highlights current regulatory views. The book covers all aspects of cancer clinical trial starting from early phase development. The early part of the book covers novel phase I dose escalation design, exposure response analysis, and innovative phase II design. This includes early development strategy for cancer immunotherapy trials. The contributors also emphasized the role of biomarker and modern era of precision medicine. The second part focuses on the late stage development. This includes the application of adaptive design, safety analysis, and quality of life (QoL) data analysis. The final part discusses current regulatory perspective and challenges. Features: Covers a wide spectrum of topics related to real-life statistical challenges in oncology clinical trials. Provides a comprehensive overview of novel statistical methods to improve trial design and statistical analysis. Detailed case studies illustrate the real life applications. Satrajit Roychoudhury is a Senior Director and a member of the Statistical Research and Innovation group in Pfizer Inc. Prior to joining; he was a member of Statistical Methodology and consulting group in Novartis. He has 11 years of extensive experience in working with different phases of clinical trial. His area of research includes early phase oncology trials, survival analysis, model informed drug development, and use of Bayesian methods in clinical trials. He is industry co-chair for the ASA Biopharmaceutical Section Regulatory-Industry Workshop and has provided statistical training in major conferences including the Joint Statistical Meetings, ASA Biopharmaceutical Section Regulatory-Industry Workshop, and ICSA Applied Statistics Symposium. Soumi Lahiri has 12 years of extensive experience in working different therapeutic areas. She is the former Director of Biostatistics in Clinical Oncology, GlaxoSmithKline. She has also worked in the oncology division of Novartis Pharmaceutical Company for two years. She is an active member of the ASA Biopharmaceutical section and former chair of the membership committee.

Also available in print format.